## **UTILITY PATENT APPLICATION TRANSMITTAL**

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
Commissioner for Patents
CP. O. Box 1450

Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 6, 2004

Date of Deposit

Signature

EL964822366US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: FRAV2003/0004 US NP

INVENTORS: Augustin Hittinger, et al

TITLE: CHEMICAL DERIVATIVES AS
ANTITELOMERASE AGENTS WHICH BIND
SPECIFICALLY TO THE G-QUADRUPLEX DNA
STRUCTURES AND THEIR APPLICATION AS A
SPECIFIC ANTICANCER AGENT

**APPLICATION ELEMENTS** 

1.	$\boxtimes$	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)				
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	56		
3.	$\boxtimes$	Drawing(s) (35 U.S.C. 113)	Total Sheets	5		
4.	Oath	or Declaration	Total Pages	2		
	a.	Unexecuted (original or copy)	J			
	b.	Copy from a prior application (37 CFR § 1.63(d))				
		i. DELETION OF INVENTOR(S)  Signed statement attached deleting application, see 37 CFR §§ 1.63(d)(2)		ed in the prior		
5.	Powe	er of Attorney	Total Pages			
	a.	Newly executed (original or copy)	_			
	b.	Copy from a prior application (37 CFR § 1	.63(d))			
6.		Microfiche Computer Program (Appendix)				

Page 2							
	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy						
	b. Paper Copy (identical to computer copy)						
	c. Statement verifying identity of above copies						
	If a CONTINUING Application, check appropriate box, and supply the requisite information:  Continuation Divisional Continuation-in-part of prior application no: , filed , Examiner , Group/Art Unit  (The cross reference has been/will be inserted on page one of the specification).						
	This application claims the benefit of U.S. Provisional Application No. 60/467,213, filed May 1, 2003 and claims priority of French Application No. 0301478 filed February 7, 2003. (The cross reference has been/will be inserted on page one of the specification).						
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
ACC	OMPANYING APPLICATION PARTS						
7. 8.	Assignment Papers (cover sheet & document(s))  37 CFR §3.73(b) Statement (when there is an assignee)						
9. 10.	<ul> <li>Verified English Translation Document (if applicable)</li> <li>Information Disclosure</li> <li>Statement (IDS)/PTO-1449</li> </ul>						
11. 12.	Preliminary Amendment Return Receipt Postcard (MPEP 503)						
13.	(Should be specifically itemized)  *Small Entity Statement(s)  (PTO/SB/09-12)  Status still proper and desired						
14.	Certified Copy of Priority Document(s) 0301478						
15.	(if foreign priority is claimed)  Other: Application Data Sheet (8 pgs.)						
CORRESPONDENCE ADDRESS							
$\boxtimes$	Customer Number or Bar Code Label 005487						
	(Insert Customer No. or Attach bar code label here)						
	Joseph Atmygavaki						
	/Joseph Strupczewski, Reg. No. 50,903 Attorney/Agent for Applicant						

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-5922 Telefax (908) 231-2626 Aventis Docket No. FRAV2003/0004 US NP

- Application Transmittal Letter

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANS	NAITTAI	Complete if Known			
LEE INAIN	DIVILLIAL	Application Number	Not Yet Assigned		
for EV	2004	Filing Date	Concurrently Filed Herewith		
for FY 2	2004	First Named Inventor	Augustin Hittinger, et al		
Patent fees are subject to	annual revision.	Examiner Name			
Applicant claims small entity status	s. See 37 CFR 1.27	Group / Art Unit .			
TOTAL AMOUNT OF PAYMENT	(\$) 1.166.00	Attorney Docket No.	FRAV2003/0004 US NP		

(\$) 1,166.00

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
Check Credit Card Money Other None	3. AI	DDITIO	NAL F	EES		
Deposit Account	Large E	ntity	Small E	ntity		
Deposit Account 18-1982	Fee Code	Fee (\$)	Fee Code	Fee (\$)		
Deposit					Fee Description Fe	e Paid
Account Name Aventis Pharmaceuticals Inc.	1051	130	2051	65	Surcharge - late filing fee or oath	
Th C mmissioner is authorized to: (check all that apply)  Charge fee(s) indicated below Credit any overpayments	1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
Charge any additional fee(s) during the pendency of this application	1053	130	1053	130	Non-English Specification	
Charge fee(s) indicated below, except for the filing fee	1812 1804	2,520 920*	1812 1804	2,520 920*	For filing a request for reexamination Requesting publication of SIR prior to	
to the above-identified deposit account			1007		Examiner action	
FEE CALCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE	1251	110	2251	55	Extension for reply within first month	
Large Entity     Small Entity     Fee       Fee     Fee     Fee     Fee Description     Paid       Code     (\$)     Code     (\$)	1252	420	2252	205	Extension for reply within second month	
1001 770 2001 375 Utility filing fee 770	1253	950	2253	465	Extension for reply within third month	
1002 340 2002 165 Design filing Fee	1254	1,480	2254	725	Extension for reply within fourth month	
1003 530 2003 260 Plant filing fee	1255	2,010	2255	985	Extension for reply within fifth month	
1004 770 2004 375 Reissue filing fee	1401	330	2401	160	Notice of Appeal	
1005 160 2005 80 Provisional filing fee	1402	330	2402	160	Filing a brief in support of an appeal	
SUBTOTAL (1) (\$) 770.00	1403	290	2403	140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
Fee Extra from Fee Claims below Paid	1452	110	2452	55	Petition to revive - unavoidable	
Total Claims 42 -20**= 22 x 18 = 396	1453	1,330	2453	650	Petition to revive - unintentional	
Independent 1 - 3**= 0 x 86 = 0	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims	1502	480	2502	235	Design issue fee	
Multiple Dependent 0 = 0	1503	640	2503	315	Plant issue fee	
	1460	130	1460	130	Petitions to the Commissioner	
Large Entity Small Entity Fee Fee Fee Fee	1807	50	1807	50	Petitions related to provisional applications	
Code (\$) Code (\$) Fee Description						
1202 18 2202 9 Claims in excess of 20	1806	180	1806	180	Submission of Information Disclosure Strnt	
1201 86 2201 42 Independent claims in excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1203 290 2203 140 Multiple dependent claim, if not paid	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86 2204 42 **Reissue independent claims over original patent	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18 2205 9 **Reissue claims in excess of 20 and over original patent	1801	770	2801	375	Request for Continued Examination (RCE)	
	1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 396.00	Other fee	(specify)			accig application	
**or number previously paid, if greater, For Reissues, see above	*Reduce	d by Basic	Filing Fee	e Paid	SUBTOTAL (3) (S)	

SUBMITTED BY Complete (If applicable)					
Name (Print/Type)	Joseph Strupczewski, Reg. No. 50,903	Registration No. (Attorney/Agent)	50,903	Telephone	(908) 231-2387
Signature	Soph thypawake			Date	02/06/2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.